NCT06427941 2026-04-17
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
Clinical Trials
20 trialsNCT03736889 2026-04-15
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
BeOne Medicines
Phase 2 Recruiting
NCT06233942 2026-04-15
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06596473 2026-04-15
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06745908 2026-04-15
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Recruiting
NCT06868732 2026-03-30
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1 Recruiting
NCT05768932 2026-03-27
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
Phase 1 Recruiting
NCT06897579 2026-03-23
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
NCT05981703 2026-03-19
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06585488 2026-03-18
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeOne Medicines
Phase 1 Recruiting
NCT07331155 2026-03-09
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT07315750 2026-01-21
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT07019675 2025-12-08
A Study of SKB518 in Patients With Lung Cancer
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 2 Recruiting
NCT05547321 2025-11-25
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Oncomatryx Biopharma S.L.
Phase 1 Recruiting
NCT07244705 2025-11-24
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
Anbogen Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07170995 2025-11-18
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT06030258 2025-04-30
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06416410 2025-04-04
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT05431270 2025-01-31
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT06471673 2024-08-26
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
BriaCell Therapeutics Corporation
Phase 1/2 Recruiting